Neoadjuvant chemotherapy with biosimilar trastuzumab in human epidermal growth factor receptor 2 overexpressed non-metastatic breast cancer: patterns of use and clinical outcomes in India

BACKGROUND: Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is associated with poor prognosis and access to anti-HER2 treatment is still a challenge in lower-middle income countries. The availability of the biosimilar trastuzumab has improved access by lowering the costs. We r...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Ecancermedicalscience
Главные авторы: Joel, Anjana, Georgy, Josh Thomas, Thumaty, Divya Bala, John, Ajoy Oommen, Chacko, Raju Titus, Rebekah, Grace, Sigamani, Elanthenral, Chandramohan, Jagan, Manipadam, Marie Therese, Cherian, Anish Jacob, Abraham, Deepak Thomas, Jacob, Paul Mazhuvanchary, Sebastian, Patricia, Backianathan, Selvamani, Singh, Ashish
Формат: Artigo
Язык:Inglês
Опубликовано: Cancer Intelligence 2021
Предметы:
Research
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC8057782/
https://ncbi.nlm.nih.gov/pubmed/33912232
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3332/ecancer.2021.1207
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы